Sung-Dae Hong is currently the Chief Executive Officer of StatLab, a portfolio company of Audax Private Equity and Linden Capital Partners. StatLab is a leading specialty developer and manufacturer providing histology, cytology, and immunohistochemistry consumables and equipment to more than 3,000 anatomical pathology laboratories throughout the United States, United Kingdom, and other international markets. Previously, Dae was President of the Laboratory Products Division at Thermo Fisher Scientific where he oversaw a global organization of 9,000 colleagues and $2.5B in revenue, with laboratory equipment and consumables serving life sciences and diagnostics applications. Dae joined Thermo Fisher as the Head of Corporate Strategy in 2011 and held multiple Vice President / General Manager roles over a 10-year span. Dae spent the first decade of his career as a management consultant at Bain & Company across four continents (Australia, Korea, Europe, U.S.) and led projects in M&A, growth strategy, and commercial due diligence. Dae was born in South Korea, immigrated to Australia as a young child, and then moved to the Boston area to attend graduate school, where he lives today. He holds honors degrees in law and finance from the University of Melbourne, and an MBA from the MIT Sloan School of Management, where he graduated as the Henry Ford II Scholar. Dae is passionate about Asian-American affairs and supporting equality of opportunities and progression in both public and private sectors and serves as a Senior Advisory Board Member of AsianUpward. Dae also serves on the Boards of the Boston Philharmonic Orchestra and the Jennifer Price Global Education Leadership Fund, and on the Advisory Board of the Harvard Extension School’s Business and Management Programs. Dae is married to his college sweetheart Maria and has two daughters, Olivia and Leah, as well as two pandemic pets, Mocha (dog) and Bailey (cat). In his spare time, Dae enjoys investing, traveling, golfing, skiing, and supporting his daughters in their endeavors.